Google
Trusted Resources: News & Events
Latest announcements and gatherings
FDA Clears Graphite Bio to Begin Trial for Gene Therapy in Sickle Cell Disease
In response to Graphite Bio’s investigational new drug (IND) application for its gene editing therapy, GPH101, the FDA will allow the pharmaceutical company to initiate a phase I/II trial in patients with sickle cell disease (SCD).
Aimed at curing SCD by targeting the gene mutation that causes damaged and sickled red blood cells, GPH101 uses CRISPR technology to cut out this mutation in the beta-globin gene and paste in the wild-type DNA sequence. The CEDAR trial will evaluate the safety, preliminary efficacy, and pharmacodynamics of GPH101 in adult and adolescent patients with severe SCD. “We are eager to initiate enrollment for the CEDAR clinical trial in early 2021, which will be a historic milestone as the first experimental treatment designed to correct the mutation that is the underlying cause of sickle cell disease,” said Graphite Bio CEO Josh Lehrer, MPhil, MD.
+myBinderRelated Content
-
NHLBI Stepping Up Efforts to Apprise SCD Patients of Therapies and TrialsWide interest in a CBS 60 Minutes story ...
-
MARAC Advisory Statement: Gene Therapy & Bone Marrow TherapiesPlease note: A previous version of this ...
-
Gene therapy may help cure sickle cell disease, study saysA gene therapy that could provide a perm...
-
Statement from FDA Commissioner on agency’s efforts to advance development of gene therapiesOnce just a theory, gene therapies are...
-
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell DiseaseBackground: Sickle cell disease is char...
-
Experimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
-
Could Gene Therapy Cure Sickle Cell Anemia?Nearly 20 years ago, scientists stunned ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
